Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

10 May 2019 07:00

Arix Bioscience Plc - Director/PDMR Shareholding

Arix Bioscience Plc - Director/PDMR Shareholding

PR Newswire

London, May 9

10 May 2019

ARIX BIOSCIENCE PLC

Director/PDMR Shareholding

Arix Bioscience plc today announces the annual award of nil cost options to certain members of management, all of which are subject to performance conditions over a three year assessment period, in accordance with the company’s Remuneration Policy.

PDMR DEALING NOTIFICATION
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1Details of the person discharging managerial responsibilities / person closely associated
a)NameJoseph Anderson
2Reason for the notification
a)Position / statusChief Executive Officer
b)Initial notification / AmendmentInitial Notification
3Details of issuer
a)NameArix Bioscience plc
b)LEI213800OVT3AHQCXNIX43
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary Shares of Arix Bioscience plc
Identification codeGB00BD045071
b)Nature of the transactionAward of nil-cost options under the Arix Bioscience plc Executive Incentive Plan ("EIP") 
c)Price(s) and volume(s)Price(s)Volume(s)
Nil578,368
d)Aggregated informationAggregated priceAggregated volume
N/A (single transaction)N/A (single transaction)
e)Date of the transaction09 May 2019
f)Place of the transactionOutside a trading venue

PDMR DEALING NOTIFICATION
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1Details of the person discharging managerial responsibilities / person closely associated
a)NameJames Hedley Rawlingson
2Reason for the notification
a)Position / statusChief Financial Officer
b)Initial notification / AmendmentInitial Notification
3Details of issuer
a)NameArix Bioscience plc
b)LEI213800OVT3AHQCXNIX43
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary Shares of Arix Bioscience plc
Identification codeGB00BD045071
b)Nature of the transactionAward of nil-cost options under the Arix Bioscience plc Executive Incentive Plan ("EIP") 
c)Price(s) and volume(s)Price(s)Volume(s)
Nil234,239
d)Aggregated informationAggregated priceAggregated volume
N/A (single transaction)N/A (single transaction)
e)Date of the transaction09 May 2019
f)Place of the transactionOutside a trading venue

PDMR DEALING NOTIFICATION
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1Details of the person discharging managerial responsibilities / person closely associated
a)NameRobert Lyne
2Reason for the notification
a)Position / statusChief Operating Officer
b)Initial notification / AmendmentInitial Notification
3Details of issuer
a)NameArix Bioscience plc
b)LEI213800OVT3AHQCXNIX43
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary Shares of Arix Bioscience plc
Identification codeGB00BD045071
b)Nature of the transactionAward of nil-cost options under the Arix Bioscience plc Executive Incentive Plan ("EIP") 
c)Price(s) and volume(s)Price(s)Volume(s)
Nil195,199
d)Aggregated informationAggregated priceAggregated volume
N/A (single transaction)N/A (single transaction)
e)Date of the transaction09 May 2019
f)Place of the transactionOutside a trading venue

For further information:

Robert Lyne Chief Operating Officer +44 (0)207 290 1050

 - Ends -

Date   Source Headline
3rd Dec 20187:00 amPRNAutolus announces update on AUTO4 and AUTO5 programmes
15th Nov 20187:00 amPRNPositive Phase 1 clinical trial results
12th Nov 20187:00 amPRNArix invests in $70m Harpoon Series C investment round
2nd Nov 201811:33 amPRNAutolus Therapeutics to Present New Data at the ASH
30th Oct 20182:11 pmPRNAura Biosciences reports positive Phase 1b/2 data
24th Oct 20187:00 amPRNLogicBio announces closing of initial public offering
19th Oct 20187:00 amPRNLogicBio prices Nasdaq IPO
10th Oct 20187:00 amPRNUpdate on LogicBio proposed IPO in the United States
1st Oct 20187:00 amPRNCo-leads $58 million Series A for VelosBio
26th Sep 20187:00 amPRNLogicBio files registration for proposed IPO in the US
18th Sep 20182:00 pmPRNUpdate on Iterum Therapeutics Phase 3 trials
12th Sep 20184:30 pmPRNAnnounces Board Changes
10th Sep 20184:24 pmPRNHolding(s) in Company
4th Sep 20187:00 amPRNChanges announced to executive team
17th Aug 20181:01 pmPRNHoldings in Company and Lock-in Agreement
10th Aug 20187:01 amPRNPositive clinical progression in Group Businesses
10th Aug 20187:00 amPRNArtios completes £65m Series B investment round
6th Aug 20187:00 amPRNArix Bioscience announces first VIPE investment
30th Jul 20187:00 amPRNInterim Results for the Six Months Ended 30 June 2018
25th Jul 20184:41 pmPRNNotice of Results
2nd Jul 20181:16 pmPRNTotal Voting Rights
26th Jun 20185:30 pmPRNAutolus annouces closing of IPO
22nd Jun 20187:07 amPRNAutolus Announces Pricing of Initial Public Offering
21st Jun 201810:22 amPRNIssue of Shares, Total Voting Rights & PDMR Notification
11th Jun 20184:23 pmPRNDirector/PDMR Shareholding
8th Jun 201811:36 amPRNUpdate on Autolus proposed NASDAQ IPO
31st May 20182:00 pmPRNLord John Hutton steps down from Board of Directors
30th May 20184:13 pmPRNIterum Therapeutics plc Closes Initial Public Offering
25th May 20187:19 amPRNIterum Therapeutics plc Prices Initial Public Offering
17th May 201812:29 pmRNSResult of AGM
17th May 20187:00 amRNSUpdate on Iterum proposed NASDAQ IPO
8th May 20187:00 amRNSAutolus Files for Proposed US IPO
2nd May 201810:10 amRNSArix notes Iterum?s proposed US IPO
23rd Apr 20187:00 amRNSAnnual Results 2017
16th Apr 20187:25 amRNSNotice of Annual Results
5th Apr 20187:00 amRNSArix to present at HC Wainwright on 10 April
4th Apr 20189:01 amRNSHolding(s) in Company
4th Apr 20189:00 amRNSTotal Voting Rights
26th Mar 20181:40 pmRNSHolding(s) in Company
26th Mar 201812:31 pmRNSArix notes positive Ph2b COPD data from Verona
23rd Mar 20189:00 amRNSHolding(s) in Company
22nd Mar 201811:51 amRNSHolding(s) in Company
21st Mar 201812:46 pmRNSHoldings in Company
21st Mar 201811:40 amRNSDirector/PDMR Shareholding
21st Mar 201811:39 amRNSHolding(s) in Company
16th Mar 201811:45 amRNSResults of General Meeting
16th Mar 20187:00 amRNSResults of Capital Raising
6th Mar 20187:00 amRNSArix notes Autolus's potential US IPO
28th Feb 201811:29 amRNSPublication of a Prospectus
28th Feb 20187:00 amRNSProposed Firm Placing, Placing and Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.